Download PDF
1 / Pages

Other users also viewed these articles

Impact of the presence and type of cardiovascular disease on the risk of mortality in type 2 diabetic patients: The DIABET-IC trial José Antonio Gimeno Orna; Ana Belén Mañas Martínez; Luis Rodríguez Padial; Manuel Anguita Sánchez; Vivencio Barrios; Javier Muñiz García; Antonio Pérez Pérez;
Endocrinol Diabetes Nutr. 2024;71:278-89
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society] Juan Pedro-Botet; Vivencio Barrios; Víctor Sánchez-Margalet; Juan Tamargo; Francisco Arrieta; José Mª Gámez; José Antonio Gimeno-Orna; Carlos Escobar; Juan José Gómez-Doblas; Antonio Pérez;
Endocrinol Diabetes Nutr. 2023;70 Supl 1:51-62
Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes Ana Romero; Gemma Llauradó; José-Miguel González-Clemente;
Endocrinol Diabetes Nutr. 2021;68:741-50